ImmunoPrecise Antibodies Ltd. (HYFT) — Capital Reinvestment Ratio

Latest as of October 2020: 1.62x

ImmunoPrecise Antibodies Ltd. (HYFT) has a Capital Reinvestment Ratio of 1.62x as of October 2020, meaning it reinvests 2% of its operating cash flow ($440.23K) in capital expenditures ($715.21K). See HYFT net asset quality score to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

1.62x
Capex / Operating Cash Flow

Operating Cash Flow

$440.23K
USD

Capital Expenditures

$715.21K
USD

Data as of

Oct 2020
Most recent filing

ImmunoPrecise Antibodies Ltd. Capital Reinvestment Ratio (2016–2016)

This chart tracks ImmunoPrecise Antibodies Ltd.'s Capital Reinvestment Ratio across 1 annual periods. Check cash flow reinvestment rate of ImmunoPrecise Antibodies Ltd. to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for ImmunoPrecise Antibodies Ltd. (2016–2016)

Year-by-year Capital Reinvestment Ratio for ImmunoPrecise Antibodies Ltd. from 2016 to 2016. For live market cap and broader valuation context, see HYFT company net worth.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2016 0.06x $284.09K $17.48K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow